1089279-91-3

Basic information

• Product Name: 1-(4-aMino-5-Methoxy-2-Methylphenyl)-N,N-diMethylpiperidin-4-aMine
• Synonyms: 1-(4-aMino-5-Methoxy-2-Methylphenyl)-N,N-diMethylpiperidin-4-aMine;1-(4-amino-3-methoxyphenyl)-N,N-dimethylpiperidin-4-amine;1-(4-amino-3-methoxyphenyl)-N,N-dimethyl-4-Piperidinamine
• CAS NO: 1089279-91-3
• Molecular Formula: C₁₄H₂₃N₃O
• Molecular Weight: 263.3785
• Mol File: 1089279-91-3.mol
• Article Data: 10

Chemical Properties

• Boiling Point: 421.1±45.0 °C(Predicted)
• Appearance: /
• Density: 1.10±0.1 g/cm3(Predicted)
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 9.28±0.20(Predicted)
• CAS DataBase Reference: 1-(4-aMino-5-Methoxy-2-Methylphenyl)-N,N-diMethylpiperidin-4-aMine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(4-aMino-5-Methoxy-2-Methylphenyl)-N,N-diMethylpiperidin-4-aMine(1089279-91-3)
• EPA Substance Registry System: 1-(4-aMino-5-Methoxy-2-Methylphenyl)-N,N-diMethylpiperidin-4-aMine(1089279-91-3)

Safety Data

• Hazardous Substances Data: 1089279-91-3(Hazardous Substances Data)

Usage

Uses

1-(4-Amino-3-methoxyphenyl)-N,N-dimethyl-4-piperidinamine is a useful reagent for organic synthesis.

Upstream product

• 446-36-6 5-fluoro-2-nitrophenol 
• 4876-59-9 4-(dimethylamino)piperidine dihydrochloride 
• 41979-39-9 4-piperidone hydrochloride 
• 761440-64-6 1-(3-methoxy-4 nitrophenyl)piperidin-4-one 
• 761440-22-6 1-(3-methoxy-4-nitrophenyl)piperidin-4-ol 
• 5382-16-1 4-HYDROXYPIPERIDINE 
• 50533-97-6 dimethyl-piperidin-4-yl-amine 
• 448-19-1 4-fluoro-2-methoxy-1-nitrobenzene 
• 1089279-90-2 1-(3-methoxy-4-nitrophenyl)-N,N-dimethylpiperidine-4-amine 

Downstream Products

• 1197958-12-5 (2-((5-chloro-2-((4-(4-(dimethylamino)piperidin-1-yl)-2-methoxyphenyl )amino)pyrimidin-4-yl)amino)phenyl)dimethylphosphine oxide 

Relevant articles and documents

Synthesis and evaluation of novel 2,4-diaminopyrimidines bearing a sulfoxide moiety as anaplastic lymphoma kinase (ALK) inhibition agents

Anaplastic lymphoma kinase (ALK) targeted therapies have demonstrated remarkable efficacy in ALK-positive lung adenocarcinomas. Here we synthesized and evaluated sixteen new 2,4-diaminopyrimidines bearing a sulfoxide moiety as anaplastic lymphoma kinase (ALK) inhibitors. The optimal compound 9e exhibited excellent antiproliferative activity against non-small cell lung cancer NCI-H2228 cells, which is better than that of Brigatinib and similar to Ceritinib. Mechanism study revealed that the optimal compound 9e decreased the mitochondrial membrane potential and arrested NCI-H2228 cells in the G0/G1 phase, finally resulting in cellular apoptosis. It is interesting that 9e could effectively inhibit the migration of NCI-H2228 cells and may be a promising leading compound for chemotherapy of metastatic cancer.

PYRIMIDINE DERIVATIVE AND USE THEREOF

The present invention provides a pyrimidine derivative and a use thereof. The pyrimidine derivative is the compound shown in formula I or a pharmaceutically acceptable salt, hydrate, solvate, metabolite or prodrug thereof, wherein, R1, R2, R3, R4 and R5 are, for example, as defined in the specification. The compound can act as an ALK inhibitor, and is for preparing an anti-tumor medicament for suppressing an anaplastic lymphoma kinase.

Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase

In the treatment of echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase positive (ALK+) non-small-cell lung cancer (NSCLC), secondary mutations within the ALK kinase domain have emerged as a major resistance mechanism to both first- and second-generation ALK inhibitors. This report describes the design and synthesis of a series of 2,4-diarylaminopyrimidine-based potent and selective ALK inhibitors culminating in identification of the investigational clinical candidate brigatinib. A unique structural feature of brigatinib is a phosphine oxide, an overlooked but novel hydrogen-bond acceptor that drives potency and selectivity in addition to favorable ADME properties. Brigatinib displayed low nanomolar IC50s against native ALK and all tested clinically relevant ALK mutants in both enzyme-based biochemical and cell-based viability assays and demonstrated efficacy in multiple ALK+ xenografts in mice, including Karpas-299 (anaplastic large-cell lymphomas [ALCL]) and H3122 (NSCLC). Brigatinib represents the most clinically advanced phosphine oxide-containing drug candidate to date and is currently being evaluated in a global phase 2 registration trial.